Thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) continues to serve as the primary treatment option for acute ischaemic stroke (AIS) within a confining therapeutic window of 3–4.5 h from stroke onset [1, 2]. Here, PLAT is linked to Stroke.